Table of Contents

1. General Indications and Logic for Haploidentical SCT.- 2. Donor Selection and  Cell Dose in Haploidentical SCT.- 3. Graft Failure and Rejection in Haploidentical SCT.- 4. Toxicity of Conditioning Regimens in Haploidentical SCT.- 4. Toxicity of Conditioning Regimens in Haploidentical SCT.- 5. An Overview of the Prophylaxis and Treatment of GVHD in Haploidentical STC.- 6. Prevention and Treatment of Infectious Complications in Haploidentical SCT.- 7. Graft versus Leukemia (GVL), Graft versus Lymphoma Effect in Haploidentical SCT.- 8. Outcome of Haploidentical SCT in Patients with Acute Leukemia.- 9. Outcome of Haploidentical SCT in Patients with Lymphoma.- 10. Applications of Haploidentical SCT in Patients with Non-malignant Diseases.- 11. Applications of Haploidentical SCT in Pediatric Patients.- 12. Innovative Approaches in Order to Increase the Success of the Haploidentical SCT. 13. Future Perspectives for Haploidentical SCT.

About the Author

Dr. Taner Demirer, MD, FACP, graduated from Ankara University Medical School in Turkey in 1984 and was trained in the USA through 1987-1997.  He completed his Internal Medicine residency at the Medical College of Wisconsin in 1989-1992 and hematology/oncology and bone marrow transplant fellowship at the University of Washington, Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, in 1992-1997. He was trained under Professors Don Thomas (Nobel laureate), Dean Buckner, Frederick Appelbaum and Rainer Storb in the clinical division of FHCRC.   He is a diplomate of the American Board of Internal Medicine and Board certified in Internal Medicine and Medical Oncology.  He was given the title of ‘Fellow of American College of Physicians (FACP) by ACP in July 1996.  He has conducted many clinical studies at the FHCRC  as principal investigator or co-investigator mainly related to peripheral blood stem cell (PBSC)  mobilization and high-dosechemotherapy (HDC) as well as autologous or allogeneic stem cell transplantations (SCT) in patients with solid tumors and hematologic malignancies.  During his career he has written many papers in the respected medical journals and books in regard to PBSC mobilization kinetics, factors influencing the PBSC collection and engraftment and allogeneic as well as autologous SCT in patients with hematologic malignancies and solid tumors.  He was chairman of the EBMT Solid Tumors Working Party (STWP) in between 2001-2007. He has conducted, chaired and published studies in related to HDC in patients with solid tumors at the EBMT STWP.  He was also board member of the Federation of the European Cancer Societies (FECS) on behalf of the EBMT through 2001-2007.  He was the president of the 29th and 41st EBMT Annual Meetings which were held in Istanbul in 2003 and 2015. He has been member of the editorial board of several international journals.  Dr. Demirer is ,currently, a professor of medicine and hematology/oncology at the Ankara University Medical School in Ankara, Turkey, and a full member of the Turkish Academy of Sciences as well as the European Academy of Sciences and Arts (EASA).